View Exam | PowerPak

1. UL is a 73-year-old woman, with a performance status of 0, presenting with a 2.5-cm lump in her left breast. Further examination reveals an additional 1 cm liver lesion. What is the preferred initial therapy for UL?

A. Radiation therapy B. Single-agent letrozole C. Single-agent abemaciclib D. Single-agent chemotherapy

2. Which of the following statements is TRUE about the PALOMA-3 trial (palbociclib vs placebo, plus fulvestrant, in women with HR+, HER2- advanced breast cancer, whose disease had progressed within 12 months of prior endocrine therapy)?

A. The median progression-free survival (PFS) was similar in both groups. B. The median overall survival (OS) was 27 months versus 14 months for palbociclib and placebo, respectively. C. The median PFS was longer in the palbociclib group but was not statistically significant. D. OS was statistically similar between groups but favored palbociclib.

3. In clinical trials, which CDK4/6 inhibitor had the LOWEST incidence of neutropenia when administered with an aromatase inhibitor?

A. All CDK4/6 inhibitors are associated with similar incidence of neutropenia. B. Abemaciclib C. Palbociclib D. Ribociclib

4. Which adverse event is much more common with abemaciclib than with ribociclib and palbociclib when administered with an aromatase inhibitor?

A. Hepatic toxicity B. Renal toxicity C. Asthenia D. Diarrhea

5. GF is a 71-year-old woman who was recently diagnosed with metastatic HR+, HER2- breast cancer. She received doxorubicin in the adjuvant setting and has left ventricular symptoms and an elongated QT interval. Which CDK4/6 inhibitors would be the LEAST appropriate for her?

A. All CDK4/6 inhibitors are equally appropriate for this patient. B. Abemaciclib C. Ribociclib D. Palbociclib

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. UL is a 73-year-old woman, with a performance status of 0, presenting with a 2.5-cm lump in her left breast. Further examination reveals an additional 1 cm liver lesion. What is the preferred initial therapy for UL?

2. Which of the following statements is TRUE about the PALOMA-3 trial (palbociclib vs placebo, plus fulvestrant, in women with HR+, HER2- advanced breast cancer, whose disease had progressed within 12 months of prior endocrine therapy)?

3. In clinical trials, which CDK4/6 inhibitor had the LOWEST incidence of neutropenia when administered with an aromatase inhibitor?

4. Which adverse event is much more common with abemaciclib than with ribociclib and palbociclib when administered with an aromatase inhibitor?

5. GF is a 71-year-old woman who was recently diagnosed with metastatic HR+, HER2- breast cancer. She received doxorubicin in the adjuvant setting and has left ventricular symptoms and an elongated QT interval. Which CDK4/6 inhibitors would be the LEAST appropriate for her?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. UL is a 73-year-old woman, with a performance status of 0, presenting with a 2.5-cm lump in her left breast. Further examination reveals an additional 1 cm liver lesion. What is the preferred initial therapy for UL?

2. Which of the following statements is TRUE about the PALOMA-3 trial (palbociclib vs placebo, plus fulvestrant, in women with HR+, HER2- advanced breast cancer, whose disease had progressed within 12 months of prior endocrine therapy)?

3. In clinical trials, which CDK4/6 inhibitor had the LOWEST incidence of neutropenia when administered with an aromatase inhibitor?

4. Which adverse event is much more common with abemaciclib than with ribociclib and palbociclib when administered with an aromatase inhibitor?

5. GF is a 71-year-old woman who was recently diagnosed with metastatic HR+, HER2- breast cancer. She received doxorubicin in the adjuvant setting and has left ventricular symptoms and an elongated QT interval. Which CDK4/6 inhibitors would be the LEAST appropriate for her?

« Return to Activity

Customers who Purchased
this Activity also Purchased